Insulin resistance and polycystic ovary syndrome

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 7, 2008, Pages 511-518

  Galluzzo, Aldo ^a   Amato, Marco Calogero ^a   Giordano, Carla ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Hyperandrogenism; Insulin resistance; PCOS; Polycystic ovary syndrome

Indexed keywords

ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION; HUMAN; INCIDENCE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 48049089593     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.05.004     Document Type: Review

References (76)

1. Chereau A. Mémoires pour servir a` l'étude des maladies des ovaires (1844), Fortin, Masson, Cie, Paris
2. Rokitansky C. A manual of pathological anatomy. vol. 2 (1844), Blanchard, Lea, Philadelphia 1855:246 (tr. by Edward Sieveking from original German edition of 1844)
3. Stein I., and Leventhal M. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29 (1935) 181-185
4. Norman R.J., Dewailly D., Legro R.S., and Hickey T.E. Polycystic ovary syndrome. Lancet 370 (2007) 685-697
5. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., and Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
6. Hull M.G. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1 (1987) 235-245
7. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91 (2006) 4237-4245
8. Rebar R., Judd H.L., Yen S.S., Rakoff J., Vandenberg G., and Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 57 (1976) 1320-1329
9. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
10. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 30 1 (2006) 13-17
11. Azziz R., Marin C., Hoq L., Badamgarav E., and Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 90 (2005) 4650-4658
12. Legro R.S., Castracane V.D., and Kauffman R.P. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 59 (2004) 141-154
13. Zawadski J.K., and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J.R., Haseltine F.P., and Merriam G.R. (Eds). Polycystic ovary syndrome (1992), Blackwell Scientific Publications, Boston 377-384
14. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
15. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., et al. POSITION STATEMENT: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91 11 (2006) 4237-4245
16. Salley K.E.S., Wickham E.P., Cheang K.I., Essah P.A., Karjane N.W., and Nestler J.E. POSITION STATEMENT: Glucose intolerance in polycystic ovary syndrome-a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 92 12 (2007) 4546-4556
17. Amato M.C., Galluzzo A., Finocchiaro S., Criscimanna A., and Giordano C. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Clin Endocrinol 69 (2008) 52-60
18. Amer S.A.K.S., Li T.C., Bygrave C., Sprigg A., Sravelos H., and Cooke I.D. An evaluation of the inter-observer and intra-observer variability of the ultrasound diagnosis of polycystic ovaries. Hum Reprod 17 (2002) 1616-1622
19. Warner M.H., Kane J.W., Atkin S.L., and Kilpatrick E.S. Dehydroepiandrosterone sulphate interferes with the Abbott Architect direct immunoassay for testosterone. Ann Clin Biochem 43 (2006) 196-199
20. Gilling-Smith C., Story H., Rogers V., and Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 47 (1997) 93-99
21. Poretsky L., Cataldo N.A., Rosenwaks Z., and Giudice L.C. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20 (1999) 535-582
22. Pugeat M., Crave J.C., Elmidani M., Nicolas M.H., Garoscio-Cholet M., Lejeune H., et al. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol. 40 4-6 (1991) 841-849
23. Puder J.J., Muller B., and Keller U. Letter re: The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 90 7 (2005) 4419-4420
24. Schoyer K.D., Liu H.C., Witkin S., Rosenwaks Z., and Spandorfer S.D. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome. Fertil Steril 88 (2007) 139-144
25. Xu L.Z., Li R., Sun Z.J., Han D.W., and Qiu D.S. The relationship between leptin, insulin-like growth factor-1 (IGF-1) and hyperinsulinemia of patients with polycystic ovarian syndrome. Sichuan Da Xue Xue Bao Yi Xue Ban 37 6 (2006) 882-885
26. Sepilian V., Crochet J., and Nagamani M. Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens. Fertil Steril 85 5 (2006) 1441-1447
27. Amato M.C., Galluzzo A., Merlino S., Mattina A., Richiusa P., Criscimanna A., et al. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome. Eur J Endocrinol 155 6 (2006) 859-865
28. Unluhizarci K., Karababa Y., Bayram F., and Kelestimur F. The investigation of insulin resistance in patients with idiopathic hirsutism. J Clin Endocrinol Metab 89 6 (2004) 2741-2744
29. Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 18 (1997) 774-800
30. Dunaif A., Diamanti-Kandarakis E., Lee A., and Wu X. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 281 (2001) E392-E399
31. Unluturk U., Harmanci A., Kocaefe C., and Yildiz B.O. The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPAR-gamma. PPAR Res 2007 (2007) 49109
32. Yilmaz M., Ergun M.A., Karakoc A., Yurtcu E., Cakir N., and Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 22 6 (2006) 336-342
33. Rosenbaum D., Haber R.S., and Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 264 (1993) E197-E202
34. Corbould A., Zhao H., Mirzoeva S., Aird F., and Dunaif A. Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 55 3 (2006) 751-759
35. Corbould A., Kim Y.-B., Youngren J.F., Pender C., Kahn B.B., Lee A., et al. Insulin resistance in the skeletal muscle of women with polycystic ovary syndrome involves both intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 288 (2005) 1047-1054
36. Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 10 2 (1996) 221-247
37. Unger R.H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144 12 (2003) 5159-5165
38. Hoffstedt J., Wahrenberg H., Thorne A., and Lonnqvist F. The metabolic syndrome is related to beta 3-adrenoceptor sensitivity in visceral adipose tissue. Diabetologia 39 7 (1996) 838-844
39. Faulds G., Ryden M., Ek I., Wahrenberg H., and Arner P. Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome. J Clin Endocrinol Metab 88 5 (2003) 2269-2273
40. Ek I., Arner P., Ryden M., Holm C., Thorne A., Hoffstedt J., et al. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 51 2 (2002) 484-492
41. Xita N., and Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 91 5 (2006) 1660-1666
42. Ibanez L., Potau N., Marcos M.V., and de Zegher F. Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age. J Clin Endocrinol Metab 84 12 (1999) 4739-4741
43. Ibanez L., de Zegher F., and Potau N. Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. J Endocrinol Invest 21 9 (1998) 558-566
44. Martens J.W., Geller D.H., Arlt W., Auchus R.J., Ossovskaya V.S., Rodriguez H., et al. Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome. J Clin Endocrinol Metab 85 11 (2000) 4338-4346
45. Ehrmann D., Barnes R., Rosenfield R., Cavaghan M., and Imperial J. Prevalence and predictors of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 (1999) 141-146
46. Dokras A., Bochner M., Hollinrake E., Markham S., Vanvoorhis B., and Jagasia D.H. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106 (2005) 131-137
47. Wild R.A., Painter P.C., Coulson P.B., Carruth K.B., and Ranney G.B. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61 (1985) 946-951
48. Paradisi G., Steinberg H.O., Hempfling A., Cronin J., Hook G., Shepard M.K., et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103 (2001) 1410-1415
49. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction-evaluated from a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand 71 (1992) 599-604
50. Birdsall M.A., Farquhar C.M., and White H.D. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126 (1997) 32-35
51. Solomon C.G., Hu F.B., Dunaif A., Rich-Edwards J.E., Stampfer M.J., Willett W.C., et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87 (2002) 2013-2017
52. Talbott E.O., Guzick D.S., Sutton-Tyrell K., McHugh-Pemu K.P., Zborowski J.V., Remsberg K.E., et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20 (2000) 2414-2421
53. Carmina E., Orio F., Palomba S., Longo R.A., Cascella T., Colao A., et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 119 4 (2006) 356.e1-356.e6
54. Boulman N., Levy Y., Leiba R., Shachar S., Linn R., Zinder O., et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89 (2004) 2160-2165
55. Escobar-Morreale H.F., Villuendas G., Botella-Carretero J.I., Alvarez-Blasco F., Sanchon R., Luque-Ramirez M., et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 21 (2006) 2257-2265
56. Carr J.J., Nelson J.C., Wong N.D., McNitt-Gray M., Arad Y., Jacobs Jr. D.R., et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology 234 (2005) 35-43
57. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy II P.F., and Fitzpatrick L.A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2568
58. Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., and Guzick D.S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
59. Moran L.J., Brinkworth G.D., and Norman R.J. Dietary therapy in polycystic ovary syndrome. Semin Reprod Med 26 1 (2008) 85-92
60. Huber-Buchholz M.M., Carey D.G., and Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84 (1999) 1470-1474
61. Galletly C., Moran L., Noakes M., Clifton P., Tomlinson L., and Norman R. Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome: a pilot study. Appetite 49 3 (2007) 590-593
62. Tsagareli V., Noakes M., and Norman R.J. Effect of a very-low-calorie diet on in vitro fertilization outcomes. Fertil Steril 86 (2006) 227-229
63. Mansfield R., Galea R., Brincat M., Hole D., and Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 79 (2003) 956-962
64. Lord J.M., Flight I.H., and Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327 (2003) 951-953
65. Palomba S., Orio Jr. F., Falbo A., Manguso F., Russo T., Cascella T., et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 7 (2005) 4068-4074
66. Aruna J., Mittal S., Kumar S., Misra R., Dadhwal V., and Vimala N. Metformin therapy in women with polycystic ovary syndrome. Int J Gynaecol Obstet 87 3 (2004) 237-241
67. Wang H.S. The role of metformin in the treatment of polycystic ovary syndrome (PCOS). Chang Gung Med J 29 5 (2006) 445-447
68. Kelly C.J., and Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 147 2 (2002) 217-221
69. Palomba S., Orio Jr. F., Nardo L.G., Falbo A., Russo T., Corea D., et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 89 10 (2004) 4801-4809
70. Lord J.M., Flight I.H., and Norman R.J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev (2003) CD003053
71. Glueck C.J., and Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf 6 2 (2007) 191-198
72. Yilmaz M., Karakoc A., Toruner F.B., Cakir N., Tiras B., Ayvaz G., et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 21 3 (2005) 154-160
73. Cheang K.I., Sharma S.T., and Nestler J.E. Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome?. Gynecol Endocrinol 22 11 (2006) 595-604
74. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and b cell function from fasting plasma glucose and insulin in man. Diabetologia 28 (1985) 412-419
75. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999) 1462-1470
76. Meyer C., McGrath B.P., and Teede H.J. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30 3 (2007) 471-478